Nevertheless, previous research has already suggested that enhanced Akt activation can play a role in resistance to cetuximab, not only in HNSCC but also in colorectal cancer and non-small cell lung cancer (35–39). Here, AKT1 is linked to non-small cell lung carcinoma.